Trial Profile
A Phase I Study of MK-2206 in Combination With Lapatinib in Refractory Solid Tumors Followed by Dose-expansion in Advanced HER2+ Breast Cancer.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; MK 2206 (Primary)
- Indications Advanced breast cancer; HER2 positive breast cancer; Solid tumours
- Focus Adverse reactions
- 29 Mar 2016 Results (n=23, dose escalation cohort) published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
- 22 Oct 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 14 Oct 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov record.